Novartis to advance novel Huntington’s disease therapy
As part of the agreement with Novartis Pharmaceuticals, PTC will receive an initial $1 billion to develop the potential first-in-class oral therapy.
List view / Grid view
As part of the agreement with Novartis Pharmaceuticals, PTC will receive an initial $1 billion to develop the potential first-in-class oral therapy.
European Pharmaceutical Review’s latest Pharma Horizons report provides insight on key sustainability developments in the pharmaceutical industry and covers topics including regulation, manufacturing and clinical development.
The analysis reveals multiple benefit in patients with type 2 diabetes and obesity with cardiovascular disease, or chronic kidney disease (CKD).
The new executive recruits at Amgen and Pfizer will support advancement in therapeutic areas including oncology and rare disease.
In this article, Steffanie Wilson, Vice President and Neuroscience Therapeutic Area Lead, Emmes Group, discusses the future of psychedelic research and highlights the impact of the FDA’s decision on Lykos Therapeutics’ NDA for its MDMA therapy to treat PTSD.
As the outsourcing market evolves, pharmaceutical businesses are reassessing their strategies to better insulate themselves against the pressure of compounding macroeconomic constraints, including a looming patent cliff, rising costs and developmental risks. Sponsors are adopting more intelligent, blended models that seamlessly integrate functional service provision (FSP), full-service outsourcing (FSO), standalone…
European Pharmaceutical Review Issue 5 includes articles on bioprocessing, biologics, sustainability, and drug formulation.
The collaboration between Novartis Pharma AG and Ratio Therapeutics aims to advance a potential best-in-class therapeutic candidate as a treatment for a difficult-to-treat cancer.
The new name and logo represent BeiGene’s vision to eliminate cancer through global collaborations to widen its reach for patients.
The acquisition is set to strengthen BioNTech’s capabilities in development and manufacture of next-generation bispecific antibodies.
Results suggest that the small molecule treatment could be an alternative to current medication that aims to prevent HIV infection and which require more frequent dosing.
A key barrier in delivering this type of therapy to patients was overcome in the first-of-a-kind T cell therapy trial, data shows.
With its novel approach for addressing a fundamental cause of eosinophilic esophagitis, approval of the biologic marks a potential new standard of care for paediatric patients.
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.